ASPN and prostate carcinoma: To elucidate the molecular interactions between secreted ASPN and prostate cancer cells, human (LNCaP) and mouse (MyC-CaP) prostate cancer cells were treated with recombinant human or mouse ASPN, respectively, for 0, 12, and 24 hours and then assessed by RNA sequencing (RNA-Seq).